Ruzaltatug Hits 16.6-Month Median PFS in HORIZON-Breast06 Phase 3 Trial
Start here
Hengrui Pharma has reported Phase 3 results from HORIZON-Breast06 for its HER2-directed antibody-drug conjugate ruzaltatug (SHR-A1811) in HER2-low advanced breast cancer. In chemotherapy-naive patients, ruzaltatug delivered a median progression-free survival of 16.6 months, compared with 6.8 months in the chemotherapy control arm. The data mark ruzaltatug as a competitor in the HER2-low metastatic setting, a field currently defined by trastuzumab deruxtecan. What remains open includes full details on overall survival, safety and subgroup outcomes, regulatory filings and approval decisions, and how clinicians will position ruzaltatug against established HER2-directed ADCs in earlier lines of therapy.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickHengrui Reports Phase 3 HORIZON-Breast06: Ruzaltatug Median PFS 16.6 Months in Chemo-Naive HER2-Low Advanced Breast Cancer
Hengrui Pharma reported Phase 3 HORIZON-Breast06 results for ruzaltatug (SHR-A1811) in HER2-low advanced breast cancer. In chemotherapy-naive patients, median PFS was 16.6 months with ruzaltatug versus 6.8 months in the chemotherapy arm.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 23 18:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.